Greg Duncan
2021
In 2021, Greg Duncan earned a total compensation of $1.1M as Chairman and Chief Executive Officer at Virios Therapeutics, a 69% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $256,250 |
|---|---|
| Option Awards | $300,668 |
| Salary | $512,500 |
| Other | $29,920 |
| Total | $1,099,338 |
Duncan received $512.5K in salary, accounting for 47% of the total pay in 2021.
Duncan also received $256.3K in non-equity incentive plan, $300.7K in option awards and $29.9K in other compensation.
Rankings
In 2021, Greg Duncan's compensation ranked 8,459th out of 12,406 executives tracked by ExecPay. In other words, Duncan earned more than 31.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,459 out of 12,406 | 32nd |
Division Manufacturing | 3,745 out of 5,492 | 32nd |
Major group Chemicals And Allied Products | 1,657 out of 2,368 | 30th |
Industry group Drugs | 1,475 out of 2,089 | 29th |
Industry Pharmaceutical Preparations | 1,097 out of 1,536 | 29th |
Source: SEC filing on April 26, 2022.
Duncan's colleagues
We found three more compensation records of executives who worked with Greg Duncan at Virios Therapeutics in 2021.
News
Virios Therapeutics CEO Greg Duncan's 2023 pay falls 39% to $567K
April 25, 2024
Virios Therapeutics CEO Greg Duncan's 2022 pay slips 15% to $937K
April 27, 2023
Virios Therapeutics CEO Greg Duncan's 2021 pay falls 69% to $1.1M
April 26, 2022
Virios Therapeutics CEO Greg Duncan receives $3.5M in 2020
April 28, 2021